Bicycle Therapeutics plc (NASDAQ:BCYC) saw an upside of 1.17% to $55.15 after adding $0.64 on Wednesday. The 5-day average trading volume is 1,113,322 shares of the company’s common stock. It has gained $56.81 in the past week. An average of 500,936 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 292,498.
BCYC’s 1-month performance is 38.00% or $15.64 on its low of $31.89 reached on 10/07/21. The company’s shares have touched a 52-week low of $17.68 and high of $55.90, with the stock’s rally to the 52-week high happening on 10/13/21. YTD, BCYC has achieved 203.68% or $37.19. However, the current price is down -1.34%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Oct 05, 8 days have gone by since the last insider trading activity for Bicycle Therapeutics plc (BCYC). Keen Nicholas (Chief Scientific Officer) most recently sold 2,178 shares at $45.10 per share on Oct 05. This transaction cost the insider $98,228. Chief Scientific Officer, Keen Nicholas, sold 1,188 shares at a price of $45.00 on Oct 01. Then, on Sep 16, Chief Scientific Officer Keen Nicholas sold 1,955 shares at a price of $45.01 per share. This transaction amounted to $87,995.
Bicycle Therapeutics plc (BCYC) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.22 for the sector.BCYC stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 107.43 while the price-to-book (PB) in the most recent quarter is 9.22.
Bicycle Therapeutics plc’s quick ratio for the period ended June 29 was 9.40, with the current ratio over the same period at 9.40 meaning that BCYC stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.21, while the total debt to equity was 0.21The trailing 12-month EBITDA margin is -500.08%. The firm’s gross profit as reported stood at $62.35 million against revenue of $10.39 million.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected BCYC to announce -$0.73 per share in earnings in its latest quarter, but it posted -$0.74, representing a -1.40% surprise. EBITDA for the quarter stood at more than -$16.94 million. BCYC stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 84.0 million, with total debt at $33.2 million. Shareholders hold equity totaling $25.51 million
Let’s look briefly at Bicycle Therapeutics plc (BCYC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 77.51% to suggest the stock is trending Overbought, with historical volatility in this time period at 92.38%.
The stock’s 5-day moving average is $52.96, reflecting a +32.23% or $13.44 change from its current price. BCYC is currently trading +25.95% above its 20-day SMA, +79.55% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +85.97% and +185.55% respectively.
Stochastic %K and %D was 92.82% and 92.33% and the average true range (ATR) pointed at 4.56. The RSI (14) points at 74.50%, while the 14-day stochastic is at 93.30% with the period’s ATR at 4.12. The stock’s 9-day MACD Oscillator is pointing at 5.57 and 8.20 on the 14-day charts.
In the most recent analyst report for Bicycle Therapeutics plc (NASDAQ: BCYC), B. Riley Securities launched coverage with a Buy rating. Analysts offering their rating for BCYC stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BCYC as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 10 have offered a “buy” rating.
What is BCYC’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $53.00 and a high of $100.00, with their median price target at $65.00. Looking at these predictions, the average price target given by analysts is for Bicycle Therapeutics plc (BCYC) stock is $69.30.